hepatocellular carcinoma
Conditions
Interventions
Neoadjuvant treatment group:TACE + lenvatinib + camrelizumab
Sponsors
Fujian Provincial Hospital
Eligibility
Sex/Gender
Male
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1) the age is >= 18 and = 10mm and no local treatment such as TACE, radiotherapy, radiofrequency, cryotherapy, etc.). 5) ECOG score: 0-1; Liver function Child-PughA level. 6) Blood routine test: absolute neutrophil count >= 1.5 × 10^9/LHb >=8.5g/L, PLT >=75 × 10^9/L. 7) No history of severe heart rate abnormalities, heart failure, etc; No history of severe respiratory dysfunction or severe pulmonary infection; There was no acute or chronic renal failure, and the creatinine clearance rate was>40mL/min. 8) The expected survival time is greater than 3 months.
Exclusion criteria
Exclusion criteria: 1) diffuse HCC caused by extensive intrahepatic metastasis, portal vein tumor thrombus located in the trunk or opposite portal vein branch of the tumor, and extrahepatic metastasis. 2) other anti-tumor treatments have been used, such as targeted drugs, PD-1, other immunotherapy, surgery, TACE, FOLFOX systemic chemotherapy, and Huaier granule therapy. 3) allergic history of components or excipients of lenvatinib and camrelizumab monoclonal antibodies. 4) patients with any active autoimmune or autoimmune diseases with expected recurrence. 5) patients are being treated with immunosuppressants or systemic hormones to achieve immunosuppression. 6) the patients with proteinuria >= 1 + will receive a 24-hour urinary protein test and those with 24-hour proteinuria >= 1g. 7) patients with other malignant tumors. 8) patients with mental illness. 9) pregnant or lactating women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| overall survival rate;recurrence-free rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| R0 resection rate;objective response rate;operation delay rate;major pathological response;safety; | — |
Countries
China
Contacts
Public ContactYan Maolin
Fujian Provincial Hospital
Outcome results
None listed